We are live on ! Find out more
OSIR

Osiris Therapeutics, Inc. Common Stock
OSIR

Delisted

OSIR was delisted on the 16th of April, 2019.

Back to rankings

1 hedge funds and large institutions have $116K invested in Osiris Therapeutics, Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% less funds holding

Funds holding: 2 → 1 (-1)

86% less capital invested

Capital invested by funds: $845K → $116K (-$729K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
1
Holders Change
-1
Holders Change %
-50%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
FIM
Freedom Investment Management
Connecticut
-$740K
Name Holding Trade Value Shares
Change 		Change in
Stake
Public Employees Retirement Association of Colorado
1
Public Employees Retirement Association of Colorado
Colorado
$116K – – –
FIM
2
Freedom Investment Management
Connecticut
– -$740K -84,110 Closed

OSIR Hedge Fund Activity: Q2 2018 in Review

1 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Osiris Therapeutics, Inc. Common Stock (OSIR) for Q2 2018, worth a combined $116K — down 86% from $845K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of OSIR and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest seller was Freedom Investment Management, exiting entirely with an estimated $740K sold.

  • 1 institutional investor held Osiris Therapeutics, Inc. Common Stock (OSIR) as of Q2 2018, down from 2 in Q1 2018.
  • Funds reported $116K of Osiris Therapeutics, Inc. Common Stock stock for Q2 2018, down 86% quarter-over-quarter.
  • 0 funds opened new Osiris Therapeutics, Inc. Common Stock positions in Q2 2018 and 1 closed out, a net change of -1 holder.
  • The largest Osiris Therapeutics, Inc. Common Stock seller in Q2 2018 was Freedom Investment Management, an estimated $740K sold.

Based on aggregated 13F filings for Q2 2018.